您的位置: 首页 > 2025年9月 第56卷 第9期 > 文字全文
2023年7月 第38卷 第7期11
目录

成年急性心力衰竭患者服药依从性预测模型的建立及评价

Establishment and evaluation of a predictive model for medication compliance in adult patients with acute heart failure

来源期刊: 广州医药 | 1268-1276 发布时间:2025-09-20 收稿时间:2025/11/3 15:38:34 阅读量:20
作者:
关键词:
急性心力衰竭 服药依从性 预测模型 影响因素 干预措施
acute heart failure medication compliance prediction model the influencing factors interventions
DOI:
10. 20223 / j. cnki. 1000-8535. 2025. 09. 016
收稿时间:
2024-08-10 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 通过建立急性心力衰竭(AHF)患者服药依从性预测模型,提高AHF患者的服药依从性和临床管理效果。方法 纳入2021年1月—2023年12月在广州市番禺区何贤纪念医院住院治疗的580例AHF患者,通过收集患者的一般人口学资料、疾病相关资料及出院后6个月的服药依从性数据,应用Logistic回归模型分析患者服药依从性的影响因素,并基于影响因素建立预测模型。结果 患者服药依从性总体良好(75%)。依从性良好组与依从性差组的年龄、独居情况、合并基础病、服药种类、疾病了解评分、治疗信心评分和自我控制信心评分比较差异有统计学意义(P<0.05)。Logistic 回归分析显示危险因素包括年龄≥60岁(OR=1.774)、独居(OR=1.871)、合并基础病≥2种(OR=1.719)和服药种类≥7种(OR=1.456)。而疾病了解评分(OR=0.923)、治疗信心评分(OR=0.946)和自我控制信心评分(OR=0.901)是保护因素(P<0.05)。基于上述因素建立的预测模型,通过ROC曲线验证,曲线下面积为0.815(95%CI:0.780~0.850),提示所构建的模型具有良好的区分度。对该模型的校准度进行评价,P=0.528,提示该预测模型拟合度良好。此外,该预测模型的一致性指数为0.738,说明模型的预测性能良好。绘制的决策曲线中,曲线位于极端线之上,当阈概率取值在9%~59%时,对应的净获益率为0~27%,提示建立的模型具有优秀的临床有效性。结论 AHF患者的服药依从性受到多种因素的影响,包括年龄、居住状态、合并基础病种类及服药种类等。
Objective To establish a predictive model for medication compliance among acute heart failure(AHF)patients in order to enhance their therapeutic compliance and optimize clinical outcomes. Methods A total of 580 AHF inpatients at He Xian Memorial Hospital in Panyu District, Guangzhou between January 2021 and December 2023 were enrolled. Demographic information, disease-specific data,as well as post-discharge medication compliance records within six-month were collected by investigators. Utilizing logistic regression analysis revealed several influential determinants affecting medication compliance which formed the basis for constructing our predictive model. Results Generally,patient compliance was good(75%). The comparison between the good compliance group and the poor compliance group showed that there were significant differences in age, living alone,combined with underlying diseases, types of medication, disease understanding score, treatment confidence score and self-control confidence score(P<0. 05). Logistic regression analysis showed that independent risk indicators including individuals aged ≥60 years(odds ratio[OR]=1. 774), those living alone(OR=1. 871), presence of two or more underlying diseases(OR=1. 719), along with consumption of seven or more medications daily(OR=1. 456). Conversely,disease awareness score(OR=0. 923), treatment confidence score(OR=0. 946), and self-control confidence score(OR=0. 901)were identified as independent protective factors. Validation using receiver operating characteristic curves demonstrated robust predictive performance with an area under curve value of 0. 815(95%CI:0. 780-0. 850), affirming its efficacy. The calibration of the model was evaluated, with a P-value of 0. 528, indicating good fit of the predictive model. Additionally, the concordance index(C-index)of the model was 0. 738, suggesting its excellent predictive performance. The decision curve analysis revealed that the curve was above the extreme lines, with a net benefit rate ranging from 0 to 27% when the threshold probability falls between. Conclusions The medication compliance of AHF patients is influenced by various factors, including age, living arrangement, the number of underlying diseases, and the number of medications taken. Targeted interventions such as enhancing patient education, simplifying treatment regimens, and improving social support can effectively improve the medication compliance of AHF patients. The predictive model established in this study provides a scientific basis for clinicians to develop more precise and effective individualized intervention measures,thereby improving the prognosis and quality of life.
        急性心力衰竭(acute heart failure,AHF)是一种严重的临床综合征,其发病急骤,病情进展迅速,给患者的生命健康带来重大影响[1]。心力衰竭的治疗不仅依赖于急性期的抢救治疗,更在于长期的药物治疗管理,以维持心脏功能,延缓病情进展。然而,AHF患者在出院后长期服药的依从性往往不佳,这不仅影响了疗效,还增加了死亡率和再住院率。因此,提高AHF患者的服药依从性成为临床管理中的重要议题。
       目前,已有研究表明,多种因素可影响心力衰竭患者的服药依从性,包括患者的年龄、疾病认知度、心理状态、居住状况、经济条件等[2-5]尽管这些因素在一定程度上解释了服药依从性的差异,但如何系统地预测并改善患者的服药依从性仍是一个亟待解决的问题。因此,建立一个科学、有效的服药依从性预测模型,对于指导临床医生进行个体化干预,提升患者服药依从性具有重要价值。
       本研究旨在通过分析成年AHF患者的临床资料,并对AHF患者出院后半年进行随访,探索影响其服药依从性的关键因素,并基于这些因素建立预测模型。该模型将能够评估患者在出院后的服药依从性风险,为临床医生提供科学依据,以便制定更加精准和有效的干预措施,从而改善患者的预后和生活质量。

1  对象与方法

1.1  研究对象

        2021年1月—2023年12月于广州市番禺区何贤纪念医院(广州市番禺区妇幼保健院)住院治疗的AHF患者被纳入本研究。根据2021年欧洲心脏病学会指南中的AHF诊断标准进行诊断[1]。纳入标准:入院后结合检查和医师诊断,符合AHF诊断标准。排除标准:(1)不同意或不能配合量表调查;(2)小于18岁。根据纳入与排除标准,720例AHF患者中最终纳入580例患者作为研究对象,并依据Morisky服药依从性评分将患者分成依从性良好组和依从性差组。本研究纳入的患者均知情并签署知情同意书,并通过伦理委员会许可(批件号:番禺区妇幼保健院医伦第202107003号),研究流程见图1。

20251110152356_8175.png
图 1   技术路线图

1.2  资料收集

       入院后从电子病历收集患者人口学资料(包括工作状态、医疗付费方式年龄、性别、受教育程度、吸烟/饮酒史、家庭人均月收入、婚姻状态、居住情况)和疾病相关资料(包括基础病史、家族史、服药情况)。其中疾病认知情况采用疾病感知问卷(Illness Perception Questionnaire-revised,IPQ-R)进行评估,问卷包含三个方面,即疾病了解、治疗信心、自我控制信心,各方面评分1~5分,评分越高表明对疾病认知度越高[6]

1.3  Morisky服药依从性量表(Morisky medication adherence scale with eight items,MMAS-8)调查

       出院后6个月,采用MMAS-8评估患者服药依从性。问卷由接受过培训的研究人员或医疗专业人士进行。中文版MMAS-8量表的Cronbach's α系数为0.723,重测信度为0.852。MMAS-8量表在多种慢性疾病患者中的应用中表现出较好的信度和效度。评分范围为0~8分,评分越高表明患者服药依从性越好[7]。具体分类标准如下:依从性良好指MMAS-8评分≥6分;依从性差指MMAS-8评分<6分。以此为标准将患者分成两组,即依从性良好组和依从性差组。

1.4  相关评价指标和方法

       以患者出院后服药依从性为因变量,人口学资料和疾病相关资料(包括年龄、独居情况、合并基础病、服药种类、性别、受教育程度、吸烟史、饮酒史、家庭人均月收入、婚姻状态、工作情况、医疗报销方式)为自变量,纳入Logistic回归模型进行AHF患者服药依从性的影响因素分析,建立预测模型,再用受试者操作特征曲线(receiver operating characteristic,ROC)评价预测效能。

1.5  样本量计算

       AHF患者服药依从性预测模型预期灵敏度80%,特异度为60%,在允许误差为8%(Δ),统计学显著性水平双侧α=0.05时,根据灵敏度计算依从性差组,根据特异度计算依从性良好组,进位取整得到,在0.05检验水准下,至少需要调查242例受试者,其中依从性差组和依从性良好组的例数分别为97例和145例。计算公式为

1.6  统计学方法

       采用R 4.1.2及SPSS 25.0软件进行数据统计学分析。计量资料符合正态分布且方差齐,以表示,采用单因素方差分析;非正态分布者以M(Q1Q3)表示,采用Kruskal-Wallis H秩和检验。计数资料以n(%)表示,采用χ 2 检验。将P<0.01的变量(即年龄、居住情况、合并基础病、服药种类、IPQ-R 评分)纳入Logistic回归模型进行影响因素分析,建立预测模型(其中年龄≥60岁、独居、合并基础病≥2种及服药种类≥7种赋值为1,年龄<60岁、非独居、合并基础病<2种及服药种类<7种赋值为0)。根据独立的风险因素构建列线图模型。采用Hosmer-Lemeshow法检验拟合优度。计算Brier得分0.19,表示模型的预测准确性较好。运用R语言中rms程序包绘制列线图。用ROC曲线、决策曲线分析(decision  curve analysis,DCA)和一致性指数(C-index)评估模型效能。P<0.05为差异具有统计学意义。

2  结 果

2.1  AHF患者服药依从性情况

       AHF患者Morisky服药依从性量表(MMAS-8)评分为(5.81±1.18)分。依从性良好组435例(75%),MMAS-8评分为(7.12±0.87)分。依从性差组145例(25%),MMAS-8评分为(4.11±1.23)分。

2.2  两组患者基线资料比较

       依从性良好组与依从性差组在年龄、独居情况、合并基础病、服药种类、疾病了解评分、治疗信心评分和自我控制信心评分上比较差异均有统计学意义(P<0.05)。
       两组性别、文化程度、吸烟史、饮酒史、家庭人均月收入、婚姻状态、工作情况、医疗报销方式资料比较差异无统计学意义(P>0.05)。依从性良好组年龄≥60岁、独居、合并基础病≥2种及服药种类≥7种比例低于依从性差组,IPQ-R 评分中疾病了解、治疗信心、自我控制信心评分高于依从性差组(P<0.05)。见表1。

          表1   两组患者基线资料比较          [n%),`x±s]

变量

依从性良好组

依从性差组

统计量

P

n=435

n=145

年龄

≥ 60

27863.9

11780.7

6.911

0.012

 

< 60岁

15736.1

2819.3

 

 

性别

 

男性

26160.0

9464.8

0.038

0.834

 

女性

17440.0

5135.2

 

 

文化程度

小学及以下

11326.0

6242.8

3.114

0.223

 

中学

19645.1

4933.8

 

 

 

大学及以上

12628.9

3423.4

 

 

吸烟史

14433.1

5940.7

0.627

0.427

 

29166.9

8659.3

 

 

饮酒史

15234.9

6846.9

1.709

0.192

 

28365.1

9453.1

 

 

家庭人均月收入

≥3 000元

15234.9

3020.7

2.107

0.348

 

1 000~2 999元

18743

6544.8

 

 

 

<1 000元

9622.1

5034.5

 

 

婚姻状态

已婚

23954.9

5840.0

1.211

0.272

 

离异/丧偶

16945.1

8760.0

 

 

居住情况

独居

18342.1

9364.1

4.904

0.026

 

非独居

15257.9

5235.9

 

 

工作情况

无业/退休

26560.9

8055.2

2.695

0.102

 

在职

17039.1

6544.8

 

 

医疗报销方式

职工医保/公费

28264.8

8659.3

0.392

0.811

 

居民医保

15335.2

5955.2

 

 

合并基础病

<2种

27863.9

4531

10.084

0.001

 

≥2种

15736.1

10069

 

 

服药种类

≥7种

9622.1

7048.3

7.836

0.006

 

<7

339(77.9)

75(51.7)

 

 

IPQ-R 评分/分

疾病了解

3.94±0.72

3.52±0.89

2.784

0.005

 

治疗信心

4.13±0.64

3.52±0.92

3.858

<0.001

 

自我控制信心

4.25±0.62

3.88±0.93

2.433

0.016

注:IPQ-R:疾病感知问卷;老年人:年龄≥60岁;吸烟:10 支/d>5年为有吸烟史;饮酒:100 g/d,>10 年为有饮酒史;合并基础病:患者合并基础病种类(2.18±0.28)种,取2种为分界点;服药种类:患者每日需服药种类(6.69±1.29)种,取7种为分界点。

 

2.3  AHF患者服药依从性的影响因素分析

       年龄≥60岁(OR=1.774)、独居(OR=1.871)、合并基础病≥2种(OR=1.719)、服药种类≥7种(OR=1.456)是患者服药依从性差的影响因素。疾病了解评分(OR=0.923)、治疗信心评分OR=0.946)、自我控制信心评分(OR=0.901)是保护因素(P<0.05)。见表2。

表2   AHF患者服药依从性的影响因素分析

变量

β

SE

Wals χ²

OR

95%CI

P

年龄(≥60岁 vs

<60岁)

0.573

0.215

7.061

1.774

1.162 ~ 2.712

0.007

居住状态(独居 vs

非独居

0.626

0.283

4.873

1.871

1.072 ~ 3.267

0.029

合并基础病(2种 vs <2种

0.542

0.228

5.582

1.719

1.096 ~ 2.692

0.018

服药种类(7种vs

<7种)

0.376

0.172

4.698

1.456

1.036 ~ 2.043

0.032

疾病了解评分

-0.078

0.039

4.321

0.923

0.857 ~ 0.994

0.037

治疗信心评分

-0.053

0.029

3.962

0.946

0.897 ~ 0.998

0.049

自我控制信心评分

-0.092

0.037

6.817

0.901

0.847 ~ 0.976

0.007

 

2.4  列线图的构建

       以服药依从性优劣为因变量,将多因素Logistic 回归分析筛选出的自变量作为预测变量,绘制列线图(图2),计算各因素的总分为0~180分,对应的风险比为0.30~0.80,总分越高,AHF患者服药依从性差的风险越大。对患者的年龄、居住状态、合并基础病、服药种类、疾病了解评分、治疗信心评分、自我控制信心评分变量取值,通过垂直线在列线图顶端的评分线得到相应的分值(默认为0~100分),随后相加所有变量的评分得到总分,通过总分在AHF患者服药依从性差风险线上得到相应概率。

20251110152523_5753.png
图 2   列线图模型

2.5  AHF患者服药依从性影响因素预测模型的建立与评价

       基于上述独立影响因素建立预测模型:LogitP=–0.868+0.573×年龄+0.626×居住状态+0.542×合并基础病+0.376×服药种类–0.078×疾病了解评分–0.053×治疗信心评分–0.092×自我控制信心评分。Hosmer-Lemeshow法检验拟合优度,P=0.528,提示该预测模型拟合度良好。此外,该预测模型的C-index为0.738,说明模型的预测性能良好。ROC的曲线下面积为0.815(95%CI0.780~0.850),提示该预测模型预测效能好。见图3。

20251110152717_6680.png
图 3   预测模型的 ROC 曲线

2.6  AHF患者服药依从性影响因素预测模型的DCA曲线

        使用R语言绘制DCA曲线,见图4。图中DCA曲线中蓝色曲线高于两条极端线,提示本预测模型在建立模型数据集中具有良好的临床有效性。当阈概率取值在 9%~59%时,对应的净获益率为0%~27%。也就是当预测模型预测较差的服药依从性的概率为9%~59%时,100例患者中有0%~27%患者能从中获益,而不损害任何其他患者的利益,表明该模型有良好的临床有效性。

20251110152824_5713.png

图 4   预测模型在建模数据集中的 DCA

3  讨 论

       本研究通过对AHF患者的临床资料进行统计分析,旨在探索影响其服药依从性的关键因素,并基于这些因素建立了服药依从性预测模型。研议。因此,加强独居患者的社区管理和家庭支持,提高其社会融入感和归属感,有助于改善其服药依从性。
       此外,合并基础病种类和服药种类也是影响服药依从性的重要因素。合并多种基础病的患者需要服用更多种类的药物,这增加了服药的复杂性和难度,从而降低了服药依从性(合并基础病≥2种:OR=1.719;服药种类≥7种:OR=1.456),这与既往研究结果相似[25-28]。因此,对于这类患者,医生应制定更为简洁有效的治疗方案,减少不必要的药物种类和剂量,同时加强患者教育,提高其对治疗方案的理解和接受[12,29-30]
       值得注意的是,疾病认知度(疾病了解评分、治疗信心评分、自我控制信心评分)对服药依从性具有显著的正面影响,这与既往研究结果相似[31-32]。疾病了解评分高、治疗信心和自我控制信心强的患者服药依从性更好。这提示我们,加强患者的健康教育,提高其疾病认知度和治疗信心,有助于改善服药依从性。
       基于上述结果,我们建立了AHF患者服药依从性预测模型,并通过ROC曲线验证了其良好的预测效能(AUC=0.815,95%CI:0.780~0.850)。究结果表明,在本研究中患者的服药依从性总体上是良好的,与其他研究相似[8-10]。此外,本研究多种因素分析显示显著影响AHF患者服药依从性的因素包括年龄、居住状态、合并基础病种类以及服药种类等。
       首先,我们发现年龄是影响服药依从性的一个重要因素。与年轻患者相比,年龄≥60岁的老年患者服药依从性较差(OR=1.774)。既往研究显示,老年患者由于多种合并症、多种处方、健忘及经济困难等多种因素,服药依从性通常较低[11-14]为60岁及以上的心力衰竭患者制定针对性干预措施,如出院前教育、随访电话提醒及社区医疗中心的面对面教学课程,有助于提高其服药依从性和健康结局[14]
       其次,居住状态也显著影响患者的服药依从性。独居患者的服药依从性明显低于非独居患者OR=1.871),这与既往研究结果相似[15-18]。这可能与独居患者缺乏社会支持和监督有关[19-24]他们可能更容易忘记服药或忽视医生的治疗建该预测模型的C-index为0.738,说明模型的预测性能良好。此外,DCA曲线也显示,该模型在中等风险阈值范围内具有最高的临床价值,能够显著提升决策过程的净获益。因此,该模型能够较为准确地评估患者在出院后的服药依从性风险,为临床医生提供科学依据,以便制定更加精准和有效的干预措施。
       然而,本研究也存在一定的局限性。首先,样本量相对较小,可能影响结果的稳定性和可靠性。在本研究中,由于样本量有限,只使用训练集来构建和验证模型,需谨慎理解模型的预测效能。未来需要进一步扩大样本量,进行多中心、大样本的研究。其次,观察时间较短,未能全面反映患者长期服药依从性的变化情况。未来可以延长观察时间,进一步验证预测模型的长期效能。
       综上所述,AHF患者的服药依从性受到多种因素的影响,包括年龄、居住状态、合并基础病种类和服药种类等。通过加强患者教育、改善治疗方案、提高社会支持等方式,可以有效改善患者的服药依从性。本研究建立的服药依从性预测模型为临床医生提供了科学依据,有助于制定更加精准和有效的干预措施,从而改善患者的预后和生活质量。
1、PONIKOWSKI%E2%80%83P%EF%BC%8CVOORS%E2%80%83A%E2%80%83A%EF%BC%8CANKER%E2%80%83S%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0A2016%E2%80%83ESC%E2%80%83Guidelines%E2%80%83for%E2%80%83the%E2%80%83diagnosis%E2%80%83and%E2%80%83treatment%E2%80%83%0Aof%E2%80%83acute%E2%80%83and%E2%80%83chronic%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERev%E2%80%83%20Esp%E2%80%83%0ACardiol%EF%BC%8C2016%EF%BC%8C69%EF%BC%8812%EF%BC%89%EF%BC%9A1167%EF%BC%8EPONIKOWSKI%E2%80%83P%EF%BC%8CVOORS%E2%80%83A%E2%80%83A%EF%BC%8CANKER%E2%80%83S%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0A2016%E2%80%83ESC%E2%80%83Guidelines%E2%80%83for%E2%80%83the%E2%80%83diagnosis%E2%80%83and%E2%80%83treatment%E2%80%83%0Aof%E2%80%83acute%E2%80%83and%E2%80%83chronic%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERev%E2%80%83%20Esp%E2%80%83%0ACardiol%EF%BC%8C2016%EF%BC%8C69%EF%BC%8812%EF%BC%89%EF%BC%9A1167%EF%BC%8E
2、KRISTINAWATI%E2%80%83B%EF%BC%8CWIJAYANTI%E2%80%83N%EF%BC%8CMARDANA%E2%80%83N%EF%BC%8E%0AImproving%E2%80%83medication%E2%80%83adherence%E2%80%83of%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83%0Afailure%E2%80%83using%E2%80%83tele-motivational%E2%80%83interviewing%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83%0ARev%E2%80%83Med%E2%80%83Pharmacol%E2%80%83Sci%EF%BC%8C2023%EF%BC%8C27%EF%BC%8821%EF%BC%89%EF%BC%9A10171-%0A10180%EF%BC%8EKRISTINAWATI%E2%80%83B%EF%BC%8CWIJAYANTI%E2%80%83N%EF%BC%8CMARDANA%E2%80%83N%EF%BC%8E%0AImproving%E2%80%83medication%E2%80%83adherence%E2%80%83of%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83%0Afailure%E2%80%83using%E2%80%83tele-motivational%E2%80%83interviewing%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83%0ARev%E2%80%83Med%E2%80%83Pharmacol%E2%80%83Sci%EF%BC%8C2023%EF%BC%8C27%EF%BC%8821%EF%BC%89%EF%BC%9A10171-%0A10180%EF%BC%8E
3、RUPPAR%E2%80%83T%E2%80%83M%EF%BC%8CCOOPER%E2%80%83P%E2%80%83S%EF%BC%8CMEHR%E2%80%83D%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedication%E2%80%83%20adherence%E2%80%83interventions%E2%80%83improve%E2%80%83%20heart%E2%80%83%0Afailure%E2%80%83mortality%E2%80%83and%E2%80%83readmission%E2%80%83rates%EF%BC%9ASystematic%E2%80%83%0Areview%E2%80%83and%E2%80%83meta-analysis%E2%80%83of%E2%80%83controlled%E2%80%83trials%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0AAm%E2%80%83Heart%E2%80%83Assoc%EF%BC%8C2016%EF%BC%8C5%EF%BC%886%EF%BC%89%EF%BC%9Ae002606%EF%BC%8ERUPPAR%E2%80%83T%E2%80%83M%EF%BC%8CCOOPER%E2%80%83P%E2%80%83S%EF%BC%8CMEHR%E2%80%83D%E2%80%83R%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedication%E2%80%83%20adherence%E2%80%83interventions%E2%80%83improve%E2%80%83%20heart%E2%80%83%0Afailure%E2%80%83mortality%E2%80%83and%E2%80%83readmission%E2%80%83rates%EF%BC%9ASystematic%E2%80%83%0Areview%E2%80%83and%E2%80%83meta-analysis%E2%80%83of%E2%80%83controlled%E2%80%83trials%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0AAm%E2%80%83Heart%E2%80%83Assoc%EF%BC%8C2016%EF%BC%8C5%EF%BC%886%EF%BC%89%EF%BC%9Ae002606%EF%BC%8E
4、KRUEGER%E2%80%83K%EF%BC%8CBOTERMANN%E2%80%83L%EF%BC%8CSCHORR%E2%80%83S%E2%80%83G%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EAge-related%E2%80%83medication%E2%80%83adherence%E2%80%83in%E2%80%83patients%E2%80%83with%20%20chronic%E2%80%83heart%E2%80%83failure%EF%BC%9AA%E2%80%83systematic%E2%80%83literature%E2%80%83review%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Cardiol%EF%BC%8C2015%EF%BC%88184%EF%BC%89%EF%BC%9A728-735%EF%BC%8EKRUEGER%E2%80%83K%EF%BC%8CBOTERMANN%E2%80%83L%EF%BC%8CSCHORR%E2%80%83S%E2%80%83G%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EAge-related%E2%80%83medication%E2%80%83adherence%E2%80%83in%E2%80%83patients%E2%80%83with%20%20chronic%E2%80%83heart%E2%80%83failure%EF%BC%9AA%E2%80%83systematic%E2%80%83literature%E2%80%83review%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Cardiol%EF%BC%8C2015%EF%BC%88184%EF%BC%89%EF%BC%9A728-735%EF%BC%8E
5、GOURZOULIDIS%E2%80%83G%EF%BC%8CKOURLABA%E2%80%83G%EF%BC%8CSTAFYLAS%E2%80%83%0AP%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83between%E2%80%83copayment%EF%BC%8Cmedication%E2%80%83%0Aadherence%E2%80%83and%E2%80%83outcomes%E2%80%83in%E2%80%83the%E2%80%83management%E2%80%83of%E2%80%83patients%E2%80%83%0Awith%E2%80%83diabetes%E2%80%83and%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHealth%E2%80%83Policy%EF%BC%8C%0A2017%EF%BC%8C121%EF%BC%884%EF%BC%89%EF%BC%9A363-377%EF%BC%8EGOURZOULIDIS%E2%80%83G%EF%BC%8CKOURLABA%E2%80%83G%EF%BC%8CSTAFYLAS%E2%80%83%0AP%EF%BC%8Cet%E2%80%83al%EF%BC%8EAssociation%E2%80%83between%E2%80%83copayment%EF%BC%8Cmedication%E2%80%83%0Aadherence%E2%80%83and%E2%80%83outcomes%E2%80%83in%E2%80%83the%E2%80%83management%E2%80%83of%E2%80%83patients%E2%80%83%0Awith%E2%80%83diabetes%E2%80%83and%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHealth%E2%80%83Policy%EF%BC%8C%0A2017%EF%BC%8C121%EF%BC%884%EF%BC%89%EF%BC%9A363-377%EF%BC%8E
6、CHILCOT%E2%80%83J%EF%BC%8CNORTON%E2%80%83S%EF%BC%8CWELLSTED%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AThe%E2%80%83factor%E2%80%83structure%E2%80%83of%E2%80%83the%E2%80%83Revised%E2%80%83%20Illness%E2%80%83Perception%E2%80%83%0AQuestionnaire%EF%BC%88IPQ-R%EF%BC%89in%E2%80%83end-stage%E2%80%83%20renal%E2%80%83%20disease%E2%80%83%0Apatients%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPsychol%E2%80%83Health%E2%80%83Med%EF%BC%8E2012%EF%BC%8C17%0A%EF%BC%885%EF%BC%89%EF%BC%9A578-588%EF%BC%8ECHILCOT%E2%80%83J%EF%BC%8CNORTON%E2%80%83S%EF%BC%8CWELLSTED%E2%80%83D%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AThe%E2%80%83factor%E2%80%83structure%E2%80%83of%E2%80%83the%E2%80%83Revised%E2%80%83%20Illness%E2%80%83Perception%E2%80%83%0AQuestionnaire%EF%BC%88IPQ-R%EF%BC%89in%E2%80%83end-stage%E2%80%83%20renal%E2%80%83%20disease%E2%80%83%0Apatients%EF%BC%BBJ%EF%BC%BD%EF%BC%8EPsychol%E2%80%83Health%E2%80%83Med%EF%BC%8E2012%EF%BC%8C17%0A%EF%BC%885%EF%BC%89%EF%BC%9A578-588%EF%BC%8E
7、MORISKY%E2%80%83D%E2%80%83E%EF%BC%8CANG%E2%80%83A%EF%BC%8CKROUSEL-WOOD%E2%80%83M%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EPredictive%E2%80%83validity%E2%80%83of%E2%80%83a%E2%80%83medication%E2%80%83adherence%E2%80%83%0Ameasure%E2%80%83in%E2%80%83an%E2%80%83outpatient%E2%80%83setting%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83%20Journal%E2%80%83%20of%E2%80%83%0Aclinical%E2%80%83hypertension%EF%BC%88Greenwich%EF%BC%8CConn%EF%BC%8E%EF%BC%89%EF%BC%8C%0A2008%EF%BC%8C10%EF%BC%885%EF%BC%89%EF%BC%9A348-354%EF%BC%8EMORISKY%E2%80%83D%E2%80%83E%EF%BC%8CANG%E2%80%83A%EF%BC%8CKROUSEL-WOOD%E2%80%83M%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EPredictive%E2%80%83validity%E2%80%83of%E2%80%83a%E2%80%83medication%E2%80%83adherence%E2%80%83%0Ameasure%E2%80%83in%E2%80%83an%E2%80%83outpatient%E2%80%83setting%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83%20Journal%E2%80%83%20of%E2%80%83%0Aclinical%E2%80%83hypertension%EF%BC%88Greenwich%EF%BC%8CConn%EF%BC%8E%EF%BC%89%EF%BC%8C%0A2008%EF%BC%8C10%EF%BC%885%EF%BC%89%EF%BC%9A348-354%EF%BC%8E
8、RASMUSSEN%E2%80%83A%E2%80%83A%EF%BC%8CWIGGERS%E2%80%83H%EF%BC%8CJENSEN%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APatient-reported%E2%80%83outcomes%E2%80%83and%E2%80%83medication%E2%80%83adherence%E2%80%83%0Ain%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83%20Heart%E2%80%83%20J%E2%80%83%0ACardiovasc%E2%80%83Pharmacother%EF%BC%8C2021%EF%BC%8C7%EF%BC%884%EF%BC%89%EF%BC%9A287-295%EF%BC%8ERASMUSSEN%E2%80%83A%E2%80%83A%EF%BC%8CWIGGERS%E2%80%83H%EF%BC%8CJENSEN%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APatient-reported%E2%80%83outcomes%E2%80%83and%E2%80%83medication%E2%80%83adherence%E2%80%83%0Ain%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83%20Heart%E2%80%83%20J%E2%80%83%0ACardiovasc%E2%80%83Pharmacother%EF%BC%8C2021%EF%BC%8C7%EF%BC%884%EF%BC%89%EF%BC%9A287-295%EF%BC%8E
9、HOEVELMANN%E2%80%83J%EF%BC%8CSLIWA%E2%80%83K%EF%BC%8CSCHAAR%E2%80%83J%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAdherence%E2%80%83to%E2%80%83heart%E2%80%83failure%E2%80%83treatment%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83%0Aperipartum%E2%80%83cardiomyopathy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EESC%E2%80%83Heart%E2%80%83Fail%EF%BC%8C%0A2024%EF%BC%8C11%EF%BC%883%EF%BC%89%EF%BC%9A1677-1687%EF%BC%8EHOEVELMANN%E2%80%83J%EF%BC%8CSLIWA%E2%80%83K%EF%BC%8CSCHAAR%E2%80%83J%E2%80%83M%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAdherence%E2%80%83to%E2%80%83heart%E2%80%83failure%E2%80%83treatment%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83%0Aperipartum%E2%80%83cardiomyopathy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EESC%E2%80%83Heart%E2%80%83Fail%EF%BC%8C%0A2024%EF%BC%8C11%EF%BC%883%EF%BC%89%EF%BC%9A1677-1687%EF%BC%8E
10、REZAEI%E2%80%83S%EF%BC%8CVAEZI%E2%80%83F%EF%BC%8CAFZAL%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8EMedication%E2%80%83%0Aadherence%E2%80%83and%E2%80%83%20health%E2%80%83literacy%E2%80%83in%E2%80%83%20patients%E2%80%83with%E2%80%83%20heart%E2%80%83%0Afailure%EF%BC%9AA%E2%80%83cross-sectional%E2%80%83survey%E2%80%83in%E2%80%83Iran%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AHealth%E2%80%83Lit%E2%80%83Res%E2%80%83Pract%EF%BC%8C2022%EF%BC%8C6%EF%BC%883%EF%BC%89%EF%BC%9Ae191-e199%EF%BC%8EREZAEI%E2%80%83S%EF%BC%8CVAEZI%E2%80%83F%EF%BC%8CAFZAL%E2%80%83G%EF%BC%8Cet%E2%80%83al%EF%BC%8EMedication%E2%80%83%0Aadherence%E2%80%83and%E2%80%83%20health%E2%80%83literacy%E2%80%83in%E2%80%83%20patients%E2%80%83with%E2%80%83%20heart%E2%80%83%0Afailure%EF%BC%9AA%E2%80%83cross-sectional%E2%80%83survey%E2%80%83in%E2%80%83Iran%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AHealth%E2%80%83Lit%E2%80%83Res%E2%80%83Pract%EF%BC%8C2022%EF%BC%8C6%EF%BC%883%EF%BC%89%EF%BC%9Ae191-e199%EF%BC%8E
11、PALLANGYO%E2%80%83P%EF%BC%8CMILLINGA%E2%80%83J%EF%BC%8CBHALIA%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedication%E2%80%83adherence%E2%80%83and%E2%80%83survival%E2%80%83among%E2%80%83hospitalized%E2%80%83%0Aheart%E2%80%83failure%E2%80%83patients%E2%80%83in%E2%80%83a%E2%80%83tertiary%E2%80%83hospital%E2%80%83in%E2%80%83Tanzania%EF%BC%9A%0AA%E2%80%83prospective%E2%80%83cohort%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Res%E2%80%83Notes%EF%BC%8C%0A2020%EF%BC%8C13%EF%BC%881%EF%BC%89%EF%BC%9A89%EF%BC%8EPALLANGYO%E2%80%83P%EF%BC%8CMILLINGA%E2%80%83J%EF%BC%8CBHALIA%E2%80%83S%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedication%E2%80%83adherence%E2%80%83and%E2%80%83survival%E2%80%83among%E2%80%83hospitalized%E2%80%83%0Aheart%E2%80%83failure%E2%80%83patients%E2%80%83in%E2%80%83a%E2%80%83tertiary%E2%80%83hospital%E2%80%83in%E2%80%83Tanzania%EF%BC%9A%0AA%E2%80%83prospective%E2%80%83cohort%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Res%E2%80%83Notes%EF%BC%8C%0A2020%EF%BC%8C13%EF%BC%881%EF%BC%89%EF%BC%9A89%EF%BC%8E
12、WU%E2%80%83J%E2%80%83R%EF%BC%8CMOSER%E2%80%83D%E2%80%83K%EF%BC%8CCHUNG%E2%80%83M%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EPredictors%E2%80%83%0Aof%E2%80%83%20medication%E2%80%83%20adherence%E2%80%83%20using%E2%80%83%20a%E2%80%83%20multidimensional%E2%80%83%0Aadherence%E2%80%83model%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0ACard%E2%80%83Fail%EF%BC%8C2008%EF%BC%8C14%EF%BC%887%EF%BC%89%EF%BC%9A603-614%EF%BC%8EWU%E2%80%83J%E2%80%83R%EF%BC%8CMOSER%E2%80%83D%E2%80%83K%EF%BC%8CCHUNG%E2%80%83M%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8EPredictors%E2%80%83%0Aof%E2%80%83%20medication%E2%80%83%20adherence%E2%80%83%20using%E2%80%83%20a%E2%80%83%20multidimensional%E2%80%83%0Aadherence%E2%80%83model%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83%0ACard%E2%80%83Fail%EF%BC%8C2008%EF%BC%8C14%EF%BC%887%EF%BC%89%EF%BC%9A603-614%EF%BC%8E
13、AGGARWAL%E2%80%83B%EF%BC%8CPENDER%E2%80%83A%EF%BC%8CMOSCA%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AFactors%E2%80%83associated%E2%80%83with%E2%80%83medication%E2%80%83adherence%E2%80%83among%E2%80%83%0Aheart%E2%80%83failure%E2%80%83patients%E2%80%83and%E2%80%83their%E2%80%83caregivers%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83%20J%E2%80%83%0ANurs%E2%80%83Educ%E2%80%83Pract%EF%BC%8C2015%EF%BC%8C5%EF%BC%883%EF%BC%89%EF%BC%9A22-27%EF%BC%8EAGGARWAL%E2%80%83B%EF%BC%8CPENDER%E2%80%83A%EF%BC%8CMOSCA%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AFactors%E2%80%83associated%E2%80%83with%E2%80%83medication%E2%80%83adherence%E2%80%83among%E2%80%83%0Aheart%E2%80%83failure%E2%80%83patients%E2%80%83and%E2%80%83their%E2%80%83caregivers%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83%20J%E2%80%83%0ANurs%E2%80%83Educ%E2%80%83Pract%EF%BC%8C2015%EF%BC%8C5%EF%BC%883%EF%BC%89%EF%BC%9A22-27%EF%BC%8E
14、MARCUM%E2%80%83Z%E2%80%83A%EF%BC%8CHANLON%E2%80%83J%E2%80%83T%EF%BC%8CMURRAY%E2%80%83M%E2%80%83D%EF%BC%8E%0AImproving%E2%80%83medication%E2%80%83adherence%E2%80%83and%E2%80%83health%E2%80%83outcomes%E2%80%83in%E2%80%83%0Aolder%E2%80%83adults%EF%BC%9AAn%E2%80%83evidence-based%E2%80%83review%E2%80%83of%E2%80%83randomized%E2%80%83controlled%E2%80%83trials%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDrugs%E2%80%83Aging%EF%BC%8C2017%EF%BC%8C34%0A%EF%BC%883%EF%BC%89%EF%BC%9A191-201%EF%BC%8EMARCUM%E2%80%83Z%E2%80%83A%EF%BC%8CHANLON%E2%80%83J%E2%80%83T%EF%BC%8CMURRAY%E2%80%83M%E2%80%83D%EF%BC%8E%0AImproving%E2%80%83medication%E2%80%83adherence%E2%80%83and%E2%80%83health%E2%80%83outcomes%E2%80%83in%E2%80%83%0Aolder%E2%80%83adults%EF%BC%9AAn%E2%80%83evidence-based%E2%80%83review%E2%80%83of%E2%80%83randomized%E2%80%83controlled%E2%80%83trials%EF%BC%BBJ%EF%BC%BD%EF%BC%8EDrugs%E2%80%83Aging%EF%BC%8C2017%EF%BC%8C34%0A%EF%BC%883%EF%BC%89%EF%BC%9A191-201%EF%BC%8E
15、杨翔,张瑗,陈阳希,等.高龄老年患者不合理用药情况调查及影响因素分析[J].医学研究生学报,2018,31(1):39-43.杨翔,张瑗,陈阳希,等.高龄老年患者不合理用药情况调查及影响因素分析[J].医学研究生学报,2018,31(1):39-43.
16、李剑萍,马天容,刘燕.慢性病空巢老人用药安全认知水平及其影响因素研究[J].护理研究,2016,30(26):3247-3250.李剑萍,马天容,刘燕.慢性病空巢老人用药安全认知水平及其影响因素研究[J].护理研究,2016,30(26):3247-3250.
17、毛晨峰,陈静,杨涛,等.独居与非独居老人生存质量及其影响因素[J].中国老年学杂志,2016,36(23):6008-6009.毛晨峰,陈静,杨涛,等.独居与非独居老人生存质量及其影响因素[J].中国老年学杂志,2016,36(23):6008-6009.
18、贾丽娜,庄海林,陈越,等.居家老年慢性病患者生活质量及影响因素分析[J].中华老年医学杂志,2013,32(12):1361-1364.贾丽娜,庄海林,陈越,等.居家老年慢性病患者生活质量及影响因素分析[J].中华老年医学杂志,2013,32(12):1361-1364.
19、%E2%80%83%20KUSASLAN%E2%80%83AVCI%E2%80%83D%EF%BC%8EEvaluation%E2%80%83of%E2%80%83the%E2%80%83%20relationship%E2%80%83%0Abetween%E2%80%83%20loneliness%E2%80%83%20and%E2%80%83%20medication%E2%80%83%20adherence%E2%80%83%20in%E2%80%83%0Apatients%E2%80%83with%E2%80%83diabetes%E2%80%83mellitus%EF%BC%9AA%E2%80%83%20cross-sectional%E2%80%83%0Astudy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Int%E2%80%83Med%E2%80%83Res%EF%BC%8C2018%EF%BC%8C46%EF%BC%888%EF%BC%89%EF%BC%9A3149-%0A3161%EF%BC%8E%E2%80%83%20KUSASLAN%E2%80%83AVCI%E2%80%83D%EF%BC%8EEvaluation%E2%80%83of%E2%80%83the%E2%80%83%20relationship%E2%80%83%0Abetween%E2%80%83%20loneliness%E2%80%83%20and%E2%80%83%20medication%E2%80%83%20adherence%E2%80%83%20in%E2%80%83%0Apatients%E2%80%83with%E2%80%83diabetes%E2%80%83mellitus%EF%BC%9AA%E2%80%83%20cross-sectional%E2%80%83%0Astudy%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Int%E2%80%83Med%E2%80%83Res%EF%BC%8C2018%EF%BC%8C46%EF%BC%888%EF%BC%89%EF%BC%9A3149-%0A3161%EF%BC%8E
20、%E2%80%83GAST%E2%80%83A%EF%BC%8CMATHES%E2%80%83T%EF%BC%8EMedication%E2%80%83%20adhe%20rence%E2%80%83%0Ainfluencing%E2%80%83factors-an%EF%BC%88updated%EF%BC%89ove%20rview%E2%80%83%20of%E2%80%83%0Asystematic%E2%80%83reviews%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESyst%E2%80%83Rev%EF%BC%8C2019%EF%BC%8C8%EF%BC%881%EF%BC%89%EF%BC%9A%0A112%EF%BC%8E%E2%80%83GAST%E2%80%83A%EF%BC%8CMATHES%E2%80%83T%EF%BC%8EMedication%E2%80%83%20adhe%20rence%E2%80%83%0Ainfluencing%E2%80%83factors-an%EF%BC%88updated%EF%BC%89ove%20rview%E2%80%83%20of%E2%80%83%0Asystematic%E2%80%83reviews%EF%BC%BBJ%EF%BC%BD%EF%BC%8ESyst%E2%80%83Rev%EF%BC%8C2019%EF%BC%8C8%EF%BC%881%EF%BC%89%EF%BC%9A%0A112%EF%BC%8E
21、PIETRZYKOWSKI%E2%80%83%20%C5%81%20%EF%BC%8C%20MICHALSKI%E2%80%83P%20%EF%BC%8C%0AKOSOBUCKA%E2%80%83A%EF%BC%8Cet%E2%80%83al%EF%BC%8EMedication%E2%80%83adherence%E2%80%83and%E2%80%83%0Aits%E2%80%83determinants%E2%80%83in%E2%80%83patients%E2%80%83after%E2%80%83myocardial%E2%80%83infarction%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83Sci%E2%80%83Rep%EF%BC%8C2020%EF%BC%8C10%EF%BC%881%EF%BC%89%EF%BC%9A12028%EF%BC%8EPIETRZYKOWSKI%E2%80%83%20%C5%81%20%EF%BC%8C%20MICHALSKI%E2%80%83P%20%EF%BC%8C%0AKOSOBUCKA%E2%80%83A%EF%BC%8Cet%E2%80%83al%EF%BC%8EMedication%E2%80%83adherence%E2%80%83and%E2%80%83%0Aits%E2%80%83determinants%E2%80%83in%E2%80%83patients%E2%80%83after%E2%80%83myocardial%E2%80%83infarction%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%E2%80%83Sci%E2%80%83Rep%EF%BC%8C2020%EF%BC%8C10%EF%BC%881%EF%BC%89%EF%BC%9A12028%EF%BC%8E
22、WU%E2%80%83J%E2%80%83R%EF%BC%8CLENNIE%E2%80%83T%E2%80%83A%EF%BC%8CCHUNG%E2%80%83M%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedication%E2%80%83%20adherence%E2%80%83%20mediates%E2%80%83%20the%E2%80%83%20relationship%E2%80%83%0Abetween%E2%80%83marital%E2%80%83status%E2%80%83and%E2%80%83cardiac%E2%80%83event-free%E2%80%83survival%E2%80%83%0Ain%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHeart%E2%80%83Lung%EF%BC%8C%0A2012%EF%BC%8C41%EF%BC%882%EF%BC%89%EF%BC%9A107-114%EF%BC%8EWU%E2%80%83J%E2%80%83R%EF%BC%8CLENNIE%E2%80%83T%E2%80%83A%EF%BC%8CCHUNG%E2%80%83M%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedication%E2%80%83%20adherence%E2%80%83%20mediates%E2%80%83%20the%E2%80%83%20relationship%E2%80%83%0Abetween%E2%80%83marital%E2%80%83status%E2%80%83and%E2%80%83cardiac%E2%80%83event-free%E2%80%83survival%E2%80%83%0Ain%E2%80%83patients%E2%80%83with%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHeart%E2%80%83Lung%EF%BC%8C%0A2012%EF%BC%8C41%EF%BC%882%EF%BC%89%EF%BC%9A107-114%EF%BC%8E
23、%E2%80%83%20ZAROWITZ%E2%80%83B%E2%80%83J%EF%BC%8CO'SHEA%E2%80%83T%EF%BC%8EChronic%E2%80%83%20obstructive%E2%80%83%0Apulmonary%E2%80%83disease%EF%BC%9APrevalence%EF%BC%8Ccharacteristics%EF%BC%8Cand%E2%80%83%0Apharmacologic%E2%80%83treatment%E2%80%83in%E2%80%83nursing%E2%80%83home%E2%80%83residents%E2%80%83with%E2%80%83%0Acognitive%E2%80%83impairment%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Manag%E2%80%83Care%E2%80%83Pharm%EF%BC%8C%0A2012%EF%BC%8C18%EF%BC%888%EF%BC%89%EF%BC%9A598-606%EF%BC%8E%E2%80%83%20ZAROWITZ%E2%80%83B%E2%80%83J%EF%BC%8CO'SHEA%E2%80%83T%EF%BC%8EChronic%E2%80%83%20obstructive%E2%80%83%0Apulmonary%E2%80%83disease%EF%BC%9APrevalence%EF%BC%8Ccharacteristics%EF%BC%8Cand%E2%80%83%0Apharmacologic%E2%80%83treatment%E2%80%83in%E2%80%83nursing%E2%80%83home%E2%80%83residents%E2%80%83with%E2%80%83%0Acognitive%E2%80%83impairment%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Manag%E2%80%83Care%E2%80%83Pharm%EF%BC%8C%0A2012%EF%BC%8C18%EF%BC%888%EF%BC%89%EF%BC%9A598-606%EF%BC%8E
24、%E2%80%83WU%E2%80%83J%E2%80%83R%EF%BC%8CMOSER%E2%80%83D%E2%80%83K%EF%BC%8EMedication%E2%80%83%20adherence%E2%80%83mediates%E2%80%83%20the%E2%80%83%20relationship%E2%80%83%20between%E2%80%83%20heart%E2%80%83%20failure%E2%80%83%0Asymptoms%E2%80%83and%E2%80%83cardiac%E2%80%83event-free%E2%80%83survival%E2%80%83in%E2%80%83patients%E2%80%83%0Awith%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Cardiovasc%E2%80%83Nurs%EF%BC%8C2018%EF%BC%8C%0A33%EF%BC%881%EF%BC%89%EF%BC%9A40-46%EF%BC%8E%E2%80%83WU%E2%80%83J%E2%80%83R%EF%BC%8CMOSER%E2%80%83D%E2%80%83K%EF%BC%8EMedication%E2%80%83%20adherence%E2%80%83mediates%E2%80%83%20the%E2%80%83%20relationship%E2%80%83%20between%E2%80%83%20heart%E2%80%83%20failure%E2%80%83%0Asymptoms%E2%80%83and%E2%80%83cardiac%E2%80%83event-free%E2%80%83survival%E2%80%83in%E2%80%83patients%E2%80%83%0Awith%E2%80%83heart%E2%80%83failure%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Cardiovasc%E2%80%83Nurs%EF%BC%8C2018%EF%BC%8C%0A33%EF%BC%881%EF%BC%89%EF%BC%9A40-46%EF%BC%8E
25、曹成霖,郭颖,洪子轩,等.慢性病共病老年人服药依从性研究的系统评价[J].南京医科大学学报(社会科学版),2024,24(4):406-410.曹成霖,郭颖,洪子轩,等.慢性病共病老年人服药依从性研究的系统评价[J].南京医科大学学报(社会科学版),2024,24(4):406-410.
26、陈维尔,邱艳,潘晓华,等.高血压共病糖尿病患者服药依从性调查及影响因素分析[J].中华全科医学,2024,22(4):601-604.陈维尔,邱艳,潘晓华,等.高血压共病糖尿病患者服药依从性调查及影响因素分析[J].中华全科医学,2024,22(4):601-604.
27、谢雪梅,高静,柏丁兮,等.老年人多重用药依从性现状及影响因素的Meta分析[J].中国全科医学,2023,26(35):4394-4403.谢雪梅,高静,柏丁兮,等.老年人多重用药依从性现状及影响因素的Meta分析[J].中国全科医学,2023,26(35):4394-4403.
28、周泓廷,黄洌彬,王新安,等.杭州市社区多重用药老年人用药依从性现况调查及其影响因素分析[J].中华现代护理杂志,2022,28(30):4173-4179.周泓廷,黄洌彬,王新安,等.杭州市社区多重用药老年人用药依从性现况调查及其影响因素分析[J].中华现代护理杂志,2022,28(30):4173-4179.
29、OSBORN%E2%80%83D%EF%BC%8CBURTON%E2%80%83A%EF%BC%8CWALTERS%E2%80%83K%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrimary%E2%80%83care%E2%80%83management%E2%80%83of%E2%80%83cardiovascular%E2%80%83%20risk%E2%80%83for%E2%80%83%0Apeople%E2%80%83with%E2%80%83severe%E2%80%83mental%E2%80%83illnesses%EF%BC%9AThe%E2%80%83%20Primrose%E2%80%83%0Aresearch%E2%80%83programme%E2%80%83including%E2%80%83cluster%E2%80%83RCT%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ASouthampton%EF%BC%88UK%EF%BC%89%EF%BC%9ANIHR%E2%80%83Journals%E2%80%83Library%EF%BC%8C2019%EF%BC%8EOSBORN%E2%80%83D%EF%BC%8CBURTON%E2%80%83A%EF%BC%8CWALTERS%E2%80%83K%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrimary%E2%80%83care%E2%80%83management%E2%80%83of%E2%80%83cardiovascular%E2%80%83%20risk%E2%80%83for%E2%80%83%0Apeople%E2%80%83with%E2%80%83severe%E2%80%83mental%E2%80%83illnesses%EF%BC%9AThe%E2%80%83%20Primrose%E2%80%83%0Aresearch%E2%80%83programme%E2%80%83including%E2%80%83cluster%E2%80%83RCT%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0ASouthampton%EF%BC%88UK%EF%BC%89%EF%BC%9ANIHR%E2%80%83Journals%E2%80%83Library%EF%BC%8C2019%EF%BC%8E
30、AJIBOLA%E2%80%83S%E2%80%83S%EF%BC%8CTIMOTHY%E2%80%83F%E2%80%83O%EF%BC%8EThe%E2%80%83influence%E2%80%83%20of%E2%80%83%0Anational%E2%80%83%20health%E2%80%83insurance%E2%80%83%20on%E2%80%83medication%E2%80%83%20adherence%E2%80%83%0Aamong%E2%80%83outpatient%E2%80%83type%E2%80%832%E2%80%83diabetics%E2%80%83in%E2%80%83southwest%E2%80%83Nigeria%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Patient%E2%80%83Exp%EF%BC%8C2018%EF%BC%8C5%EF%BC%882%EF%BC%89%EF%BC%9A114-119%EF%BC%8EAJIBOLA%E2%80%83S%E2%80%83S%EF%BC%8CTIMOTHY%E2%80%83F%E2%80%83O%EF%BC%8EThe%E2%80%83influence%E2%80%83%20of%E2%80%83%0Anational%E2%80%83%20health%E2%80%83insurance%E2%80%83%20on%E2%80%83medication%E2%80%83%20adherence%E2%80%83%0Aamong%E2%80%83outpatient%E2%80%83type%E2%80%832%E2%80%83diabetics%E2%80%83in%E2%80%83southwest%E2%80%83Nigeria%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Patient%E2%80%83Exp%EF%BC%8C2018%EF%BC%8C5%EF%BC%882%EF%BC%89%EF%BC%9A114-119%EF%BC%8E
31、%E2%80%83%20JI%E2%80%83Y%EF%BC%8CATAKAN%E2%80%83M%E2%80%83M%EF%BC%8CYAN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EReallocating%E2%80%83%0Ajust%E2%80%8310min%E2%80%83to%E2%80%83moderate-to-vigorous%E2%80%83physical%E2%80%83activity%E2%80%83%0Afrom%E2%80%83other%E2%80%83components%E2%80%83of%E2%80%8324-hour%E2%80%83movement%E2%80%83behaviors%E2%80%83%0Aimproves%E2%80%83cardiovascular%E2%80%83health%E2%80%83in%E2%80%83adults%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83%0APublic%E2%80%83Health%EF%BC%8C2024%EF%BC%8C24%EF%BC%881%EF%BC%89%EF%BC%9A1768%EF%BC%8E%E2%80%83%20JI%E2%80%83Y%EF%BC%8CATAKAN%E2%80%83M%E2%80%83M%EF%BC%8CYAN%E2%80%83X%EF%BC%8Cet%E2%80%83al%EF%BC%8EReallocating%E2%80%83%0Ajust%E2%80%8310min%E2%80%83to%E2%80%83moderate-to-vigorous%E2%80%83physical%E2%80%83activity%E2%80%83%0Afrom%E2%80%83other%E2%80%83components%E2%80%83of%E2%80%8324-hour%E2%80%83movement%E2%80%83behaviors%E2%80%83%0Aimproves%E2%80%83cardiovascular%E2%80%83health%E2%80%83in%E2%80%83adults%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83%0APublic%E2%80%83Health%EF%BC%8C2024%EF%BC%8C24%EF%BC%881%EF%BC%89%EF%BC%9A1768%EF%BC%8E
32、LEVIC%E2%80%83M%EF%BC%8CBOGAVAC-STANOJEVIC%E2%80%83N%EF%BC%8CUBAVIC%E2%80%83%0AS%EF%BC%8Cet%E2%80%83al%EF%BC%8EPha%20rmacothe%20rapy%E2%80%83%20lite%20racy%E2%80%83%20level%E2%80%83%20and%E2%80%83%0Apredictors%E2%80%83of%E2%80%83low%E2%80%83literacy%E2%80%83among%E2%80%83diabetes%E2%80%83mellitus%E2%80%83type%E2%80%832%E2%80%83%0Apatients%E2%80%83in%E2%80%83Serbia%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Public%E2%80%83Health%EF%BC%8C2023%EF%BC%8C%0A23%EF%BC%881%EF%BC%89%EF%BC%9A1822%EF%BC%8ELEVIC%E2%80%83M%EF%BC%8CBOGAVAC-STANOJEVIC%E2%80%83N%EF%BC%8CUBAVIC%E2%80%83%0AS%EF%BC%8Cet%E2%80%83al%EF%BC%8EPha%20rmacothe%20rapy%E2%80%83%20lite%20racy%E2%80%83%20level%E2%80%83%20and%E2%80%83%0Apredictors%E2%80%83of%E2%80%83low%E2%80%83literacy%E2%80%83among%E2%80%83diabetes%E2%80%83mellitus%E2%80%83type%E2%80%832%E2%80%83%0Apatients%E2%80%83in%E2%80%83Serbia%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Public%E2%80%83Health%EF%BC%8C2023%EF%BC%8C%0A23%EF%BC%881%EF%BC%89%EF%BC%9A1822%EF%BC%8E
1、番禺区重点学科(专科)医疗卫生项目(2021-Z04-008)()
上一篇
下一篇
出版者信息








《广州医药》公众号
目录